Figure 3. BioPROTACE6 degrades E6, disrupts HPV(+) proliferation and induces ISG15 mRNA.
(a) Schematic representing PROTACE6 interacting with CUL2. (b) Confocal microscopic images of HEK293T cells transfected with E6-GFP alone, or in combination with VHL, PROTACE6(VHL-A5), or mutPROTACE6 (VHLTLK157-159AAA-A5) and imaged after 48 hours (N=3). (c) The dose-dependent titration of PROTACE6 was assessed for cellular proliferation in CaSki cells 48 hours post-transfection, using WST-1 reagent in a 96-well plate (N=4, error bars ± SD). A curve was fitted using Prism GraphPad. (d) CaSki cells transfected with Empty control, A2, C11, and PROTACE6 were assessed 48 hours later for cellular proliferation using WST. (e) Induction of ISG15 mRNA using RT-qPCR (N=3). A one-way ANOVA was performed, and error bars represent ± SD. (* p < 0.0332, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001).